Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02581553 · ClinicalTrials.gov registry record · Phase 1

Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability

A Phase 1 study of Healthy, sponsored by Ardea Biosciences.

Completed
Registry status
Phase 1
Development phase
116
Enrollment target
1
Study location

NCT02581553 is a Phase 1 study of Healthy that has completed, run by Ardea Biosciences. The registered enrollment target is 116 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02581553, a Phase 1 study of Healthy, has completed, sponsored by Ardea Biosciences.

COMPLETED
Registry status
Phase 1
Development phase
116 participants
Enrollment target
1
Study location

Study Summary

This study will assess relative bioavailability of lesinurad/allopurinol fixed dose combination (FDC), its individual components and the effect of food.

Conditions Studied

Healthy

Interventions

  • DRUG lesinurad/allopurinol 200/300 FDC tablets
  • DRUG lesinurad 200 mg
  • DRUG allopurinol 300 mg
  • DRUG lesinurad/allopurinol 200/200 FDC tablets
  • DRUG allopurinol 200 mg

Study Locations (1)

Texas

  • - Austin

Trial Details

FieldValue
Enrollment Target 116 participants
Start Date 2015-10
Est. Completion 2016-08
Phase Phase 1

Sponsor

Ardea Biosciences

32 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02581553

The ClinicalTrials.gov registry entry for NCT02581553 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (82% lower). The listed sponsor is Ardea Biosciences, which has 32 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 5 interventions - of which lesinurad/allopurinol 200/300 FDC tablets is the first listed.

NCT02581553 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT02581553 about?

NCT02581553 is a clinical study titled "Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability". This study will assess relative bioavailability of lesinurad/allopurinol fixed dose combination (FDC), its individual components and the effect of food.

What is the current status of trial NCT02581553?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 116 participants. The study started on 2015-10. Estimated completion is 2016-08.

What conditions does trial NCT02581553 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT02581553?

The interventions under investigation include: lesinurad/allopurinol 200/300 FDC tablets (DRUG), lesinurad 200 mg (DRUG), allopurinol 300 mg (DRUG), lesinurad/allopurinol 200/200 FDC tablets (DRUG), allopurinol 200 mg (DRUG).

Who is sponsoring clinical trial NCT02581553?

This trial is sponsored by Ardea Biosciences, which has 32 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02581553 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Healthy

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.